

## Icatibant vs Inhibitor C1 esterase kallikrein for COVID-1-

**Author(s):** Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

**Question:** Should Icatibant compared to Inhibitor C1 esterase / kallikrein be used for COVID-1?

**Setting:** Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Icatibant	Inhibitor C1 esterase / kallikrein	Relative (95% CI)	Absolute (95% CI)	
<b>All-cause mortality</b>											
1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>b</sup>	none	0/10 (0.0%)	1/10 (10.0%)	<b>RR 0.33</b> (0.02 to 7.32)	<b>67 fewer per 1.000</b> (from 98 fewer to 632 more)	⊕○○○ VERY LOW
<b>Length of stay in hospital</b>											
1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>b</sup>	none	10	10	-	<b>SMD 0.3 lower</b> (1.19 lower to 0.58 higher)	⊕○○○ VERY LOW
<b>Duration of hospitalization in intensive care</b>											
1 <sup>1</sup>	randomised trials	serious <sup>a</sup>	not serious	not serious	very serious <sup>b</sup>	none	10	10	-	<b>SMD 0.21 lower</b> (1.09 lower to 0.67 higher)	⊕○○○ VERY LOW

### Explanations

a. Downgraded of one level for high risk of performance bias and unclear risk of reporting bias

b. Downgraded of two levels for very small sample size

### References

1. Mansour E, Palma AC, Ulaf RG, Ribeiro LC, Bernardes AF, Nunes TA, et al. Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 A proof-of-concept study. medRxiv. 2020:2020.08.11.20167353.